 Sign in | Create an account

About Tools Developers Help Europe PMC plus

Search life-sciences literature (43,274,515 articles, preprints and more)

Advanced search

Abstract Type II Hypersensitivity Reaction

Free full text 
Bajwa SF 1, Mohammed RH 2 
Continuing Education
Activity Author information 
Introduction
Study Guide from StatPearls Publishing, Treasure Island (FL), 23 Oct 2020
Etiology PMID: 33085411
Epidemiology Books & documents Free to read
Pathophysiology
Share this article    
Histopathology

History and Physical

Evaluation
Abstract
Treatment / Management Type II hypersensitivity reaction refers to an antibody-mediated immune reaction in which antibodies (IgG or IgM) a
Differential Diagnosis directed against cellular or extracellular matrix antigens, resulting in cellular destruction, functional loss, or tissue
damage. Damage can occur via three different mechanisms: Antibody binding to cell surface receptors and altering
Prognosis
its activity. Activation of the complement pathway. Antibody dependant cellular cytotoxicity.
Complications

Deterrence and Patient

Education Free full text
Enhancing Healthcare
Team Outcomes
StatPearls [Internet].
Review Questions
Show details
References

Citations & impact

Similar Articles
Bulk Download
Bulk download StatPearls data from FTP

Type II Hypersensitivity Reaction

Shammas F. Bajwa; Reem H. Mohammed.

Author Information

Last Update: July 4, 2023.

Continuing Education Activity

Type II hypersensitivity reaction refers to an antibody-mediated immune reaction in which antibodies (IgG or IgM) a
directed against cellular or extracellular matrix antigens, resulting in cellular destruction, functional loss, or damage
to tissues. Damage can occur through multiple mechanisms. This activity defines the involved pathogenic
mechanisms, the clinical presentations, evaluation, and management of common forms of type II hypersensitivity
reactions and highlights the role of the interprofessional team in the care of these patients.

Objectives:
This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in o
Describe the immune pathogenesis of type II hypersensitivity reactions.
privacy notice and cookie policy.
 Feedback
Review the evaluation of the most common forms of type II hypersensitivity reactions.
 Outline the various treatment options for the most common forms of type II hypersensitivity reaction.

Summarize the importance of collaboration and communication amongst the interprofessional team to
enhance the care of patients with a type II hypersensitivity reaction.

Access free multiple choice questions on this topic.

Introduction
Type II hypersensitivity reaction refers to an antibody-mediated immune reaction in which antibodies (IgG or IgM) are
directed against cellular or extracellular matrix antigens, resulting in cellular destruction, functional loss, or tissue
damage. Damage can occur via three different mechanisms:

Antibody binding to cell surface receptors and altering its activity

Activation of the complement pathway[1]

Antibody dependant cellular cytotoxicity[2]

Etiology
The type II hypersensitivity reaction develops in response to cell surface modifications or matrix-associated antigens
generating antigenic epitopes that are regarded as foreign by the immune system. The most common causes include
medications like penicillin, thiazides, cephalosporins, and methyldopa. The drug molecule either binds to the surface
of cells resulting in a neoantigen or alters the epitopes of the existing self-antigen on the cell surface. This directs the
immune system to recognize modified antigens as foreign, with the breakdown of the immune tolerance and the
production of antibodies directed to self-antigens.[3]

Immune tolerance is the phenomenon by which the immune system recognizes its antigens and does not generate
an antibody response against its antigens. Factors that contribute to the breakdown of tolerance promote the
production of antibodies against self-antigens.[4]

Epidemiology
Epidemiological data regarding hypersensitivity reactions are scarce. One-third of the adverse reactions occurring
due to drugs are, in fact, hypersensitivity reactions. These hypersensitive reactions can prove to be lethal and can
also prolong hospitalizations. Genetic predisposing factors remain unexplored, but it is possible that we can identify
high-risk populations with advancing genetic studies in the future.[5] Epidemiology also varies according to the
underlying cause of type II hypersensitivity reaction, such as in the case of hemolytic disease of the newborn; despite
advanced immunoprophylaxis, an estimated 1 to 3 in 1000 Rh-negative women still develop alloimmunization today.
[6]

Pathophysiology
Coombs and Gell described immune-mediated immediate hypersensitivity reactions (IHR) as an antibody-driven
response that occurs within 24 hours and classified them into type I, II, III, and IV hypersensitivity reactions. These
reactions involve IgE, IgM, and IgG antibodies. In type II hypersensitivity, following exposure to the inciting agent,
autoantibodies are produced (IgG and IgM) to the host cells (sensitization phase), promoting a series of pathogenic
outcomes (effector phase).[7]

The pathophysiology of type II hypersensitivity reactions can be broadly classified into three types:

Cell depletion or destruction without inflammation

Inflammation mediated by complement or Fc receptor

Cellular dysfunction by antibodies[1]

The process involves a series of immune-mediated events that might take different forms.

Cell Depletion or Destruction Without Inflammation:

Antibodies can bind to the target cell's surface, particularly IgG antibodies. Through their Fc portion, they bind to their
respective Fc receptor on the surface of macrophages and thus act as an opsonin. An opsonin is any molecule that
enhances the phagocytosis of any substance. Thus by binding to both the target cell and the Fc receptor of the
macrophage, it activates the macrophage and causes it to phagocytose the target cell.[8]

Antibodies can also bind to the target cell and activate the complement pathway resulting in the formation of
complement component C3b, which also acts as an opsonin and binds to the receptors on the surface of
This website requires
macrophages. This,cookies,
in turn, and the limited
activates processing of
the macrophages your personal
causing data inthe
them to engulf order
cellto function.
resulting inBy using the
depletion of site
the you are agreeing to this as outlined in o
privacy notice and cookie policy.
cell.[8]
 Antibodies can also bind to the target cell resulting in complement pathway activation and formation of the
membrane attack complex involving complement components C5b6789. The membrane attack complex creates a
channel to induce the lysis of cells. A single channel is sufficient to induce lysis of anucleated cells like erythrocytes,
but nucleated cells require multiple membrane attack complexes to destroy such cells.[9]

Antibody dependant cell-mediated cytotoxicity is a phenomenon by which antibodies bind to the target cell and then
the effector cells of the immune system. These are primarily natural killer cells that attach to the Fc portion of the
antibody and then are activated, releasing perforins and granzymes, causing lysis of the target cell.

This type of cell depletion or destruction without inflammation is seen in autoimmune hemolytic anemia,
autoimmune thrombocytopenia, certain blood transfusion reactions, and erythroblastosis fetalis.

Inflammation Mediated by Complement or Fc Receptor:

Antibodies can activate the complement pathway by binding to self-antigens resulting in the formation of
complement components C3a and C5a, which act as chemotactic factors for neutrophils, causing the recruitment of
neutrophils to the site and resulting in the activation of neutrophils. These neutrophils then release enzymes and
reactive oxygen species, which damage the tissues. For example, in Goodpasture syndrome, autoantibodies are
directed against collagen in glomerular and alveolar basement membranes. The binding of these antibodies leads to
strong activation of the complement system, which recruits leukocytes resulting in inflammation.[10]

Antibodies against foreign antigens can also trigger complement activation and inflammation by a mechanism of
molecular mimicry. This is the hallmark of acute rheumatic fever in which antibodies directed against streptococcal
antigens structurally mimic cardiac myosin in the human heart, leading to cross-reactivity of these antibodies against
bacterial and host antigens and therefore binding to the myosin and damaging the heart tissue.[11]

Cellular Dysfunction by Antibodies

Autoantibodies bind to the receptors on target cells, causing dysfunction without causing inflammation or
destruction. For example, in Graves disease, the autoantibodies bind to the thyrotropin receptor on thyroid follicular
cells resulting in the overproduction of thyroid hormones. Normally the production of thyrotropin by the pituitary is
regulated by levels of thyroid hormones in the blood, but these antibodies lead to autonomous production of thyroid
hormones by the follicular cells, which are not inhibited by high levels of thyroid hormones in the blood resulting in
much higher levels than cause symptoms of thyrotoxicosis.[12]

In myasthenia gravis, autoantibodies directed against the nicotinic acetylcholine receptor do not allow acetylcholine
to bind to its receptor on muscle cells leading to muscle weakness.[13]

Histopathology
Immunohistopathology of type II hypersensitive reactions illustrates antibody-mediated cytotoxicity (IgG and IgM)
together with other disease-specific features. In Graves disease, there is diffuse hyperplasia of the follicular cells of
the thyroid with an increased follicle/stroma ratio.[14] Acute rheumatic fever with the involvement of the
myocardium shows dense valvular inflammatory infiltrate and Aschoff bodies, which is the characteristic finding of
rheumatic inflammation of the heart.[15]

In Goodpasture syndrome, renal biopsy under a light microscope shows crescentic glomerulonephritis.
Immunofluorescence shows the linear deposition of IgG with a complement along the basement membrane.[16] In
pemphigus vulgaris, histopathology shows suprabasal clefting and the "tombstone" appearance of the basal cells.
Immunofluorescence shows intercellular deposition of antibodies against IgG and C3.[17]

History and Physical

History and physical examination findings differ based on the disease category presented. With type
II hypersensitivity reactions, during the history taking, the patient might report repeated blood transfusions, blood
group or rhesus incompatibility, or a history of recent drug intake. The patient might clinically present with features
of autoimmunity, e.g., immune thrombocytopenia (characterized by bleeding disorders), autoimmune hemolytic
anemia (characterized by jaundice), and other blood dyscrasias (autoimmune neutropenia).[33][34] I

n myasthenia gravis, the patient could have symptoms suggestive of generalized muscle weakness with difficulty in
mobilizing, eating, speech, and carrying out routine activities.[18]

Evaluation
The evaluation of this form of immediate hypersensitivity reaction depends on the nature of the inciting factor and a
combination of clinical presentations and investigative data to establish a proper diagnosis.

Surveying
This an antibody
website requires immune-mediated
cookies, and the limitedreaction represents
processing of your the key feature
personal data inconsidering the history
order to function. and the site you are agreeing to this as outlined in o
By using
examination. One of the most
privacy notice and cookie policy. common examples of type II hypersensitivity is the one following drug intake in
 patients with drug-induced lupus. In this type, anti-red blood cell or anti-dsDNA antibodies are produced as a result
of a drug attaching to red blood cells resulting in drug-induced systemic lupus erythematosus (SLE).

The evaluation includes the following: Complete blood cell count surveying hemoglobin (autoimmune hemolytic
anemia), red blood cell count, neutrophils, lymphocytes, and platelets for cytopenias, and an assessment of
immunoglobulins with a quantitative assay for IgG, IgM, and IgE depending on the type of hypersensitivity reaction.
Animals, plants, food, and environmental pollutants can be used in skin prick tests, and a radioallergosorbent test
(RAST for IgE) can be done.[19] Drug allergies can also be detected through intradermal tests, such as hypersensitivity
to ceftriaxone and carbamazepine.[20][21][20]

The detection of autoantibodies can be assessed in systemic autoimmune diseases like SLE and rheumatoid arthritis
(RA). Autoantibodies can also be done against specific organs, e.g., autoantibody against islet cells in diabetes
mellitus, thyroid-stimulating hormone (TSH) receptor antibody to differentiate it from other causes of thyrotoxicosis,
and acetylcholine receptor antibody test (highly specific for myasthenia gravis).[22][23]

Treatment / Management
The treatment following diagnosis will depend on the treatment guidelines and recommendations for each disease
subset. Avoidance of the inciting trigger in case of adverse drug events, hemolysis, or drug-induced autoimmune
disease is very important. Management of cytopenias should be done according to a defined protocol. Systemic
glucocorticoids represent another important intervention to suppress antibody response and prevent tissue damage.

Examples of Management Protocols

In the case of a drug-induced adverse event, drug-induced lupus, or cytopenias, the drug should be discontinued.

Antibiotic therapy should be started in cases with acute rheumatic fever to eradicate the carriage of group A
streptococcus. Penicillin V and benzylpenicillin are primarily used for this purpose. Oral cephalosporins are used as
an alternative therapy for penicillin-allergic patients. Symptomatic treatment of acute manifestations like arthritis
(with NSAIDs), carditis (with aspirin or oral prednisone), and chorea (with diazepam) should be provided. Prevention
of progression of cardiac damage by giving prophylaxis against future group A streptococcal infections should be
done. Benzathine penicillin G is administered intramuscularly for prophylaxis.[24]

In immune-mediated thyrotoxicosis (Graves disease), antithyroid drugs, including propylthiouracil and methimazole,
are started. Radioiodine ablation and surgical excision should also be considered. Glucocorticoids are used for
ophthalmopathy.[25]

In myasthenia gravis, acetylcholinesterase inhibitors like pyridostigmine are started. Immunosuppressive therapy
(like corticosteroids) is used for the patient's refractory to pyridostigmine therapy. Thymectomy is considered in
patients refractory to drug therapy. Plasma exchange and intravenous immune globulin should be given in
myasthenic crises.[26]

Differential Diagnosis
The differential diagnosis of type II hypersensitivity reactions largely depends on the presentation patterns specific to
each disease category. In addition, knowledge of the other different types of hypersensitivity reactions and the
clinical presentations of each is essential.

The following are the most common examples:

Hemolytic anemias
Cytopenias (thrombocytopenia- neutropenia)

Drug toxicities
Autoimmune diseases

Allergic reactions
Infections[27]

Endocrinopathies
Neuromuscular disorders (congenital, familial, degenerative, inflammatory, iatrogenic, neoplastic, and
autoimmune)[25][26][28]
Valvular heart disease[27]

Prognosis
The prognosis of type II hypersensitivity reactions differs based on timely diagnosis, carefully considering the possible
This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in o
differential diagnoses. Additionally, it varies from one disease category to another. For instance, the overall prognosis
privacy notice and cookie policy.
of hemolytic disease of the newborn is good if identified and treated promptly. In the case of myasthenia gravis, most
 patients have a near-normal life span with the current treatment modalities. Fifty years ago, the mortality rate was
around 50% to 80% in the myasthenic crisis, and now it has reduced substantially to 4.47%.[29]

Complications
If left untreated, patients may develop tissue or organ damage, which depends on the clinical presentation, e.g.,
cytopenias might contribute to infections, bleeding tendencies, and severe anemias. Acute rheumatic fever may lead
to rheumatic heart disease with valvular lesions (stenosis and regurgitation).[30] Myasthenia crisis may prove fatal if
not treated promptly with intubation and glucocorticoid therapy.[31]

Deterrence and Patient Education

Patients should be educated about the diagnosed disease and the importance of taking medications to avoid serious
complications that can prove to be life-threatening. They should be advised to avoid taking new medications without
checking with the medical provider. Patients with myasthenia gravis should be advised to comply with the treatment
plan to ensure that the disease remains well controlled.[32]

Enhancing Healthcare Team Outcomes

Type II hypersensitivity reactions require close collaboration and communication amongst the interprofessional team
involving clinicians (MDs, DOs, NPs, and PAs), immunologists, nurses, pharmacists, and laboratory staff. This
will provide a patient-centered approach, improve outcomes and patient safety, and enhance team performance. In
the case of drug allergy, the pharmacist should check the patient's medication record, and the nursing staff should be
vigilant and should have the patient clarify any prior allergic reaction to drugs.[33]

Nurses can serve as patient contact points and coordinate activities between interprofessional team members. All
persons on the care team must be able to communicate with any other team member in the event of any concerns
or changes in patient status. All interventions and observations must be documented in the patient's health record by
every team member so everyone has access to the same updated information regarding the case. This
interprofessional approach will help drive the best possible patient outcomes with the fewest adverse events. [Level
5]

Review Questions
Access free multiple choice questions on this topic.
Comment on this article.

References
1. Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. Allergy
Asthma Clin Immunol. 2011 Nov 10;7 Suppl 1(Suppl 1):S1. [Abstract]

2. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-
infected cells. J Infect Dis. 1983 Nov;148(5):785-94. [Abstract]

3. Viel S, Pescarmona R, Belot A, Nosbaum A, Lombard C, Walzer T, Bérard F. A Case of Type 2 Hypersensitivity to
Rasburicase Diagnosed with a Natural Killer Cell Activation Assay. Front Immunol. 2018;9:110. [Abstract]

4. Schwartz RH. Historical overview of immunological tolerance. Cold Spring Harb Perspect Biol. 2012 Apr
01;4(4):a006908. [Abstract]

5. Demoly P, Gomes ER. Drug hypersensitivities: definition, epidemiology and risk factors. Eur Ann Allergy Clin
Immunol. 2005 Jun;37(6):202-6. [Abstract]

6. Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management
and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017 Jul;10(7):607-616. [Abstract]

7. Tomasiak-Łozowska MM, Klimek M, Lis A, Moniuszko M, Bodzenta-Łukaszyk A. Markers of anaphylaxis - a

systematic review. Adv Med Sci. 2018 Sep;63(2):265-277. [Abstract]

8. Mosser DM, Zhang X. Measuring opsonic phagocytosis via Fcγ receptors and complement receptors on
macrophages. Curr Protoc Immunol. 2011 Nov;Chapter 14:Unit 14.27. [Abstract]

9. Koski CL, Ramm LE, Hammer CH, Mayer MM, Shin ML. Cytolysis of nucleated cells by complement: cell death
displays multi-hit characteristics. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3816-20. [Abstract]

This 10.
website requires cookies,K,and
Kościelska-Kasprzak the limited
Bartoszek processing
D, Myszka of your M,
M, Zabińska personal
Klingerdata in order
M. The to function.
complement By using
cascade and the site you are agreeing to this as outlined in o
renal
privacy notice andArch
disease. cookie policy.Ther Exp (Warsz). 2014 Feb;62(1):47-57. [Abstract]
Immunol
 11. Guilherme L, Kalil J, Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart
disease. Autoimmunity. 2006 Feb;39(1):31-9. [Abstract]

12. McIver B, Morris JC. The pathogenesis of Graves' disease. Endocrinol Metab Clin North Am. 1998 Mar;27(1):73-
89. [Abstract]

13. Romi F, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups.
Curr Opin Immunol. 2017 Dec;49:9-13. [Abstract]

14. Schlüter A, Eckstein AK, Brenzel A, Horstmann M, Lang S, Berchner-Pfannschmidt U, Banga JP, Diaz-Cano S.
Noninflammatory Diffuse Follicular Hypertrophy/Hyperplasia of Graves Disease: Morphometric Evaluation in an
Experimental Mouse Model. Eur Thyroid J. 2018 Jun;7(3):111-119. [Abstract]

15. DECKER JP, HAWN CV, ROBBINS SL. Rheumatic activity as judged by the pressence of Aschoff bodies in auricular
appendage of patients with mitral stenosis. I. Anatomic aspects. Circulation. 1953 Aug;8(2):161-9. [Abstract]

16. Zhao J, Yan Y, Cui Z, Yang R, Zhao MH. The immunoglobulin G subclass distribution of anti-GBM autoantibodies
against rHalpha3(IV)NC1 is associated with disease severity. Hum Immunol. 2009 Jun;70(6):425-9. [Abstract]

17. Kumar SJ, Nehru Anand SP, Gunasekaran N, Krishnan R. Oral pemphigus vulgaris: A case report with direct
immunofluorescence study. J Oral Maxillofac Pathol. 2016 Sep-Dec;20(3):549. [Abstract]

18. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and
Epidemiology. Neurol Clin. 2018 May;36(2):253-260. [Abstract]

19. Agulló-García A, Cubero Saldaña JL, Colás Sanz C. Series of 12 cases of wheat-dependent exercise-induced
allergy in Aragon, Spain. Rev Clin Esp (Barc). 2019 May;219(4):184-188. [Abstract]

20. Mori F, Liccioli G, Piccorossi A, Sarti L, Barni S, Giovannini M, Azzari C, Manfredi M, Novembre E. The Diagnosis of
Ceftriaxone Hypersensitivity in a Paediatric Population. Int Arch Allergy Immunol. 2019;178(3):272-276.
[Abstract]

21. Braun V, Darrigade AS, Milpied B. Positive patch test reaction to carbamazepine after a very long delay. Contact
Dermatitis. 2018 Oct;79(4):240-241. [Abstract]

22. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in
myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976 Nov;26(11):1054-9.
[Abstract]

23. Wang KY, Friedman DF, DaVeiga SP. Immediate hypersensitivity reaction to human serum albumin in a child
undergoing plasmapheresis. Transfusion. 2019 Jun;59(6):1921-1923. [Abstract]

24. Webb RH, Grant C, Harnden A. Acute rheumatic fever. BMJ. 2015 Jul 14;351:h3443. [Abstract]

25. Nicolle MW. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome. Continuum (Minneap Minn). 2016
Dec;22(6, Muscle and Neuromuscular Junction Disorders):1978-2005. [Abstract]

26. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol.
2014;122:269-90. [Abstract]

27. Arnold MH, Tyndall A. Poststreptococcal reactive arthritis. Ann Rheum Dis. 1989 Aug;48(8):686-8. [Abstract]

28. Garg N, Yiannikas C, Hardy TA, Belaya K, Cheung J, Beeson D, Reddel SW. Late presentations of congenital
myasthenic syndromes: How many do we miss? Muscle Nerve. 2016 Oct;54(4):721-7. [Abstract]

29. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis
and myasthenic crisis in US hospitals. Neurology. 2009 May 05;72(18):1548-54. [Abstract]

30. Parks T, Kado J, Miller AE, Ward B, Heenan R, Colquhoun SM, Bärnighausen TW, Mirabel M, Bloom DE, Bailey RL,
Tukana IN, Steer AC. Rheumatic Heart Disease-Attributable Mortality at Ages 5-69 Years in Fiji: A Five-Year,
National, Population-Based Record-Linkage Cohort Study. PLoS Negl Trop Dis. 2015;9(9):e0004033. [Abstract]

31. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M,
Palace J, Richman DP, Verschuuren J, Narayanaswami P. International consensus guidance for management of
myasthenia gravis: Executive summary. Neurology. 2016 Jul 26;87(4):419-25. [Abstract]

32. Juhn MS. Myasthenia gravis. Diagnostic methods and control measures for a chronic disease. Postgrad Med.
1993 Oct;94(5):161-4, 167-71, 174. [Abstract]

33. Blumenthal KG, Li Y, Hsu JT, Wolfson AR, Berkowitz DN, Carballo VA, Schwartz JM, Marquis KA, Elshaboury R,
Gandhi RG, Lambl BB, Freeley MM, Gruszecki A, Wickner PG, Shenoy ES. Outcomes from an inpatient beta-
lactam allergy guideline across a large US health system. Infect Control Hosp Epidemiol. 2019 May;40(5):528-
535. [Abstract]
This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in o
privacy notice and cookie policy.
 Disclosure: Shammas Bajwa declares no relevant financial relationships with ineligible companies.

Disclosure: Reem Mohammed declares no relevant financial relationships with ineligible companies.

Copyright © 2023, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the
work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute
this article, provided that you credit the author and journal.

ID: NBK563264 PMID: 33085411

Citations & impact 

Similar Articles 

Follow us

   
News blog Technical blog Twitter YouTube

About Tools Developers Help

About Europe PMC Tools overview Developer resources Help using Europe P
Funders ORCID article claiming Articles RESTful API Search syntax refere
Become a funder Journal list Grants RESTful API Contact us
Governance Grant finder API case studies
Roadmap External links service SOAP web service
Outreach RSS feeds Annotations API
Annotations OAI service
Annotations submission service Bulk downloads
Developers Forum

Let us know how we are doing.

Europe PMC is part of the ELIXIR infrastructure

Europe PMC is an ELIXIR Core Data Resource Learn more >

Europe PMC is a service of the Europe PMC Funders' Group, in partnership with the European Bioinformatics Institute; and in coo
Information at the U.S. National Library of Medicine (NCBI/NLM) . It includes content provided to the PMC Internatio

Europe PMC is a GBC Contact us | Privacy | Terms of use | Copyright | Accessibility

global core biodata
resource.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in o
privacy notice and cookie policy.